You are using an outdated browser. Please upgrade your browser to improve your experience.
Shaping the Future of NMSC

Non-melanoma skin cancers (NMSCs), including basal cell carcinoma and cutaneous squamous cell carcinoma, are typically managed with Mohs micrographic surgery, but advanced cases may require alternative approaches due to inoperability or progression

Non-melanoma skin cancers (NMSCs), including basal cell carcinoma and cutaneous squamous cell carcinoma, are typically managed with Mohs micrographic surgery, but advanced cases may require alternative approaches due to inoperability or progression

Shaping the Future of NMSC

by Med Learning Group

What is it about?

Non-melanoma skin cancers (NMSCs), including basal cell carcinoma and cutaneous squamous cell carcinoma, are typically managed with Mohs micrographic surgery, but advanced cases may require alternative approaches due to inoperability or progression. The immunogenicity of NMSCs makes them strong candidates for immune checkpoint inhibitor therapy, with agents like cemiplimab and pembrolizumab demonstrating favorable efficacy and tolerability. Emerging strategies, including neoadjuvant and intralesional immunotherapy, are under investigation to enhance tumor response prior to or in place of surgery. Continued development of these immunotherapeutic approaches offers the potential to improve outcomes in patient care.

App Details

Version
1.1
Rating
NA
Size
297Mb
Genre
Education Medical
Last updated
September 28, 2025
Release date
May 24, 2025
More info

App Store Description

Non-melanoma skin cancers (NMSCs), including basal cell carcinoma and cutaneous squamous cell carcinoma, are typically managed with Mohs micrographic surgery, but advanced cases may require alternative approaches due to inoperability or progression. The immunogenicity of NMSCs makes them strong candidates for immune checkpoint inhibitor therapy, with agents like cemiplimab and pembrolizumab demonstrating favorable efficacy and tolerability. Emerging strategies, including neoadjuvant and intralesional immunotherapy, are under investigation to enhance tumor response prior to or in place of surgery. Continued development of these immunotherapeutic approaches offers the potential to improve outcomes in patient care.

Disclaimer:
AppAdvice does not own this application and only provides images and links contained in the iTunes Search API, to help our users find the best apps to download. If you are the developer of this app and would like your information removed, please send a request to takedown@appadvice.com and your information will be removed.